TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02468739
Drug: Ganglioside-monosialic acid
Normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
Study: NCT00929539
Drug: JTT-130
Normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT02302807
Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Study: NCT02302807
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT02302807
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT02302807
Drug: Vinflunine
Normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT04421222
Drug: EPI-7386 (BID)
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily oral dose of EPI-7386
Study: NCT04421222
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily dose of abiraterone acetate
Study: NCT04421222
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily dose of apalutamide
Study: NCT01423370
Drug: Cialis
Normalized name: Cialis
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg oral once daily
Study: NCT02428270
Drug: GSK2256098
Normalized name: GSK2256098
DrugBank: GSK2256098 (DB16106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitor of focal adhesion kinase (FAK)
Study: NCT02428270
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
Study: NCT00134459
Drug: Bifeprunox
Normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02092831
Drug: GDC-0941
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose market image tablet of hardness 1
Study: NCT02092831
Drug: GDC-0941
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose market image tablet of hardness 2
Study: NCT02092831
Drug: GDC-0941
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose market image tablet of hardness 3
Study: NCT02092831
Drug: GDC-0941
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose Phase 2 tablet formulation
Study: NCT02742441
Drug: Vehicle Foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Foam containing no active drug
Study: NCT02709902
Drug: Adapalene/BP gel, 0.3%/2.5%
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel
Study: NCT02468674
Drug: bimagrumab
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Study: NCT05338515
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT03980041
Drug: IPI-549 (eganelisib)
Normalized name: Ipilimumab
DrugBank: IPI-549 (DB16296)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IPI-549 (40mg QD) administered orally in 28-day cycles
Study: NCT03980041
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
Study: NCT00672009
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
Study: NCT01034631
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
Study: NCT01034631
Drug: BNC105P
DrugBank: BNC105 (DB06313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC105P, up to 16 mg/m\^2
Study: NCT00001849
Drug: Pentetreotide
Normalized name: pentetreotide
DrugBank: Pentetreotide (DB12602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.
Study: NCT00001849
Drug: 18F-DOPA
Normalized name: (-)-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.
Study: NCT00001849
Drug: 18-FDG
Normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDG PET scan of body
Study: NCT03991975
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a multi-target receptor tyrosine kinase inhibitor.
Study: NCT00313261
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00776503
Drug: VORINOSTAT
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vorinostat; 400mg once daily; increasing duration (7-10-14 days)
Study: NCT04218695
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT02576600
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCI
Study: NCT02939391
Drug: KW-6356
Normalized name: KW-7158
DrugBank: KW-6356 (DB17080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03238534
Drug: Omeprazole 20mg
Normalized name: OMEPRAZOLE 20MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily administration Omeprazole 20mg (per os, 30' before breakfast).
Study: NCT00005938
Drug: exatecan mesylate
Normalized name: mesylate
DrugBank: Exatecan (DB12185)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00094172
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
Study: NCT00002734
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002734
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00850343
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) injection
Study: NCT02821169
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
Study: NCT00008203
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00008203
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00008203
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00343759
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will take 14 days of Lapatinib prior to definitive surgery.
Study: NCT00828932
Drug: Lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004099
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02695732
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
Study: NCT02468232
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
Study: NCT02468232
Drug: Placebo to Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
Study: NCT02083315
Drug: Morphine 10 mg
Normalized name: morphine 10 MG/ML
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 10 mg IV x 1 dose
Study: NCT02037997
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75mg/m2 ivgtt D1
Study: NCT02037997
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pemetrexed 500mg/m2 ivgtt D1
Study: NCT02037997
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150mg qd
Study: NCT01421706
Drug: Sibutramine-clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sibutramine-clopidogrel
Study: NCT01309945
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
Study: NCT01309945
Drug: Placebo matching with BMS-820836
Normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
Study: NCT01309945
Drug: BMS-820836
Normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
Study: NCT01309945
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
Study: NCT01309945
Drug: Placebo matching with Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
Study: NCT02164838
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03738696
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
Study: NCT03738696
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
Study: NCT00758849
Drug: Fipamezole
Normalized name: Fipamezole
DrugBank: Fipamezole (DB06585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
Study: NCT00318994
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00146523
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03600350
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
Study: NCT03600350
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
Study: NCT02499666
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
Study: NCT02392364
Drug: Intravitreal Aflibercept Injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01136954
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
Study: NCT03478280
Drug: Brodalumab
Normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Study: NCT04013464
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10-20mg/d
Study: NCT03513328
Drug: Thiotepa--single daily dose
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
Study: NCT03513328
Drug: Thiotepa--escalated dose
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
Study: NCT00401596
Drug: Xolair (omalizumab)
Normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02127853
Drug: gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
Study: NCT01587820
Drug: Intra-arterial cisplatin
Normalized name: methotrexate
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
Study: NCT01587820
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
Study: NCT04149626
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
Study: NCT04149626
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation using midazolam (initial bolus dose followed by continuous infusion)
Study: NCT00236587
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02538081
Drug: Risperidone plus Placebo
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard of care including Risperidone plus Placebo
Study: NCT02538081
Drug: Risperidone plus DMXB-A
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard of care including Risperidone plus DMXB-A
Study: NCT00437177
Drug: apomorphine
Normalized name: Apomorphine
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
Study: NCT01458236
Drug: Beraprost Sodium 314d Modified Release Tablets
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
Study: NCT01324752
Drug: PA21 and Losartan with Food
Normalized name: Losartan Potassium and Hydrochlorothiazide Tablets
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
Study: NCT01324752
Drug: No PA21; Losartan with food
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The maximum dose of Losartan will be 100 mg/day.
Study: NCT01324752
Drug: PA21 with food and Losartan 2 hours later
Normalized name: losartan and amlodipine
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
Study: NCT01134042
Drug: Fluticasone Furoate/Vilanterol Inhalation Powder
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
Study: NCT01134042
Drug: Fluticasone Furoate Inhalation Powder
Normalized name: fluticasone furoate Dry Powder Inhaler
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
Study: NCT01134042
Drug: Fluticasone Propionate Inhalation Powder
Normalized name: fluticasone propionate Dry Powder Inhaler
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
Study: NCT03434262
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV).
Study: NCT03434262
Drug: ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally (PO).
Study: NCT03434262
Drug: sonidegib
Normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO.
Study: NCT03434262
Drug: trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO.
Study: NCT02534961
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
Study: NCT02166697
Drug: candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: candesartan cilexetil tablets
Study: NCT03437083
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT00939653
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
Study: NCT00939653
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
Study: NCT00939653
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000 x 2 days.
Study: NCT00939653
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients \>3 years of age
Study: NCT00048048
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Differing doses and frequencies of sc administration